We at Aizant use out-licensing as a key business model to expand the reach of our developed products by partnering with companies for distribution and commercialization in targeted markets or regions.
Out-Licensing Opportunities
We offer out-licensing for both approved and pipeline products, giving partners access to high-quality, innovative pharmaceutical formulations without the need to engage in the entire development process. Our licensing agreements are customizable, focusing on specific regions such as the US, Canada, Europe, or ROW (Rest of World), enabling companies to expand their portfolios without incurring R&D and regulatory costs.
Mutually Beneficial Terms
Out-licensing agreements typically include upfront payments, milestone payments, and royalties, ensuring mutually beneficial terms. We provide opportunities across multiple therapeutic areas, including oncology, complex generics, NCEs (New Chemical Entities), and specialty products. Our partners benefit from Aizant’s strong product pipeline and cutting-edge technologies.
